Literature DB >> 30207018

Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention.

Scott C Bell1,2,3, Joseph S Elborn4,5,6, Catherine A Byrnes7,8.   

Abstract

Interest in bronchiectasis has increased over the past two decades, as shown by the establishment of disease-specific registries in several countries, the publication of management guidelines and a growing number of clinical trials to address evidence gaps for treatment decisions. This review considers the evidence for defining and treating pulmonary exacerbations, the approaches for eradication of newly identified airway pathogens and the methods to prevent exacerbations through long-term treatments from a pragmatic practice-based perspective. Areas for future studies are also explored. Watch the video abstract.
© 2018 Asian Pacific Society of Respirology.

Keywords:  Pseudomonas aeruginosa; bacterial infection; bronchiectasis; eradication; pulmonary exacerbations

Mesh:

Substances:

Year:  2018        PMID: 30207018     DOI: 10.1111/resp.13398

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  9 in total

1.  Management of Australian Adults with Bronchiectasis in Tertiary Care: Evidence-Based or Access-Driven?

Authors:  Simone K Visser; Peter T P Bye; Greg J Fox; Lucy D Burr; Anne B Chang; Chien-Li Holmes-Liew; Paul King; Peter G Middleton; Graeme P Maguire; Daniel Smith; Rachel M Thomson; Enna Stroil-Salama; Warwick J Britton; Lucy C Morgan
Journal:  Lung       Date:  2019-11-05       Impact factor: 2.584

2.  Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.

Authors:  Vikas Goyal; Keith Grimwood; Robert S Ware; Catherine A Byrnes; Peter S Morris; I Brent Masters; Gabrielle B McCallum; Michael J Binks; Heidi Smith-Vaughan; Kerry-Ann F O'Grady; Anita Champion; Helen M Buntain; André Schultz; Mark Chatfield; Paul J Torzillo; Anne B Chang
Journal:  Lancet Respir Med       Date:  2019-08-16       Impact factor: 30.700

3.  A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial.

Authors:  Judy Martina Bradley; Rohan Anand; Brenda O'Neill; Kathryn Ferguson; Mike Clarke; Mary Carroll; James Chalmers; Anthony De Soyza; Jamie Duckers; Adam T Hill; Michael R Loebinger; Fiona Copeland; Evie Gardner; Christina Campbell; Ashley Agus; Alistair McGuire; Roisin Boyle; Fionnuala McKinney; Naomi Dickson; Danny F McAuley; Stuart Elborn
Journal:  Trials       Date:  2019-12-19       Impact factor: 2.279

4.  Effect of Bronchodilator and Steroid Use on Heart Disease and Stroke Risks in a Bronchiectasis-Chronic Obstructive Pulmonary Disease Overlap Cohort: A Propensity Score Matching Study.

Authors:  Jun-Jun Yeh; Yu-Cih Yang; Chung Y Hsu; Chia-Hung Kao
Journal:  Front Pharmacol       Date:  2019-11-27       Impact factor: 5.810

5.  Network Pharmacology Analysis of the Therapeutic Mechanisms Underlying Beimu-Gualou Formula Activity against Bronchiectasis with In Silico Molecular Docking Validation.

Authors:  Xin Shen; Hong Li; Wen-Jun Zou; Jian-Ming Wu; Long Wang; Wei Wang; Hui Chen; Ling-Li Zhou; Yuan-Hui Hu; Xu-Hua Qin; Jing Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-01-05       Impact factor: 2.629

6.  Utility of a personalised Bronchiectasis Action Management Plan (BAMP) for children with bronchiectasis: protocol for a multicentre, double-blind parallel, superiority randomised controlled trial.

Authors:  Julie M Marchant; Anne B Chang; Kobi L Schutz; Lesley Versteegh; Anne Cook; Jack Roberts; Peter S Morris; Stephanie T Yerkovich; Gabrielle B McCallum
Journal:  BMJ Open       Date:  2021-12-22       Impact factor: 2.692

7.  Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults.

Authors:  Helen Usansky; Esther Yoon; Ariel Teper; Jun Zou; Carlos Fernandez
Journal:  Clin Pharmacol Drug Dev       Date:  2022-04-11

8.  Clinical and research priorities for children and young people with bronchiectasis: an international roadmap.

Authors:  Anne B Chang; Jeanette Boyd; Leanne Bell; Vikas Goyal; I Brent Masters; Zena Powell; Christine Wilson; Angela Zacharasiewicz; Efthymia Alexopoulou; Andrew Bush; James D Chalmers; Rebecca Fortescue; Adam T Hill; Bulent Karadag; Fabio Midulla; Gabrielle B McCallum; Deborah Snijders; Woo-Jung Song; Thomy Tonia; Keith Grimwood; Ahmad Kantar
Journal:  ERJ Open Res       Date:  2021-07-19

9.  Exacerbations and Changes in Physical Activity and Sedentary Behaviour in Patients with Bronchiectasis after 1 Year.

Authors:  Victoria Alcaraz-Serrano; Ane Arbillaga-Etxarri; Patricia Oscanoa; Laia Fernández-Barat; Leticia Bueno; Rosanel Amaro; Elena Gimeno-Santos; Antoni Torres
Journal:  J Clin Med       Date:  2021-03-12       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.